Effects of cyclic nucleotide phosphodiesterase IV inhibitor, Ro20,1724, on pancreatic exocrine secretion in dog.
1. The effects of the cyclic nucleotide phosphodiesterase (PDE) inhibitors, Ro20,1724, 3-isobutyl-1-methylxanthine (IBMX), trifluoperazine (TFP) and amrinone on pancreatic exocrine secretion were investigated in anaesthetized dogs in comparison with those of secretion and cholecystokinin octapeptide (CCK-8). 2. Ro20,1724 (1-30 nmol/kg), IBMX (3-30 nmol/kg), secretin (0.01-0.1 pmol/kg) or CCK-8 (0.1-1 pmol/kg) injected i.a. elicited a dose-dependent increase in the secretion of pancreatic juice, but TFP and amrinone (up to 1 mumol/kg) did not. 3. The bicarbonate concentration in pancreatic juice was increased and the protein concentration was decreased by Ro20,1724, IBMX and secretin. Cholecystokinin octapeptide increased the protein concentration but did not alter the bicarbonate concentration. 4. Ro20,1724 and IBMX elicited more than the respective additive secretory response when added together with secretin, although the stimulatory effects of CCK-8 with Ro20,1724 and IBMX were additive. 5. Ro20,1724 and IBMX increased cyclic AMP concentration but did not affect cyclic GMP concentration. 6. These results suggest that Ro20,1724 and IBMX have secretory properties on pancreatic exocrine glands of the dog, which may be mediated through an increase in cyclic AMP subsequent to inhibition of PDE activity. Furthermore, pancreatic PDE enzymes in the dog may be mainly type IV.
Iwatsuki
K
K
Department of Pharmacology, Shinshu University School of Medicine, Matsumoto, Japan.
Ren
L M
LM
Chiba
S
S
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone / Q000494:pharmacology*; D000676:Amrinone / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D001639:Bicarbonates / Q000378:metabolism; D000242:Cyclic AMP / Q000032:analysis; D006152:Cyclic GMP / Q000032:analysis; D004285:Dogs; D004347:Drug Interactions; D005260:Female; D007269:Injections, Intra-Arterial; D008297:Male; D010189:Pancreatic Juice / Q000187:drug effects* / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D011506:Proteins / Q000378:metabolism; D012633:Secretin / Q000502:physiology; D012844:Sincalide / Q000502:physiology; D014268:Trifluoperazine / Q000494:pharmacology
D001639:Bicarbonates; D010726:Phosphodiesterase Inhibitors; D011506:Proteins; D012633:Secretin; D014268:Trifluoperazine; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; D000242:Cyclic AMP; D006152:Cyclic GMP; D000676:Amrinone; D012844:Sincalide; D015056:1-Methyl-3-isobutylxanthine